Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by Aviva PLC

Aviva PLC raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 1,508.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 31,069 shares of the medical research company's stock after purchasing an additional 29,137 shares during the quarter. Aviva PLC owned 0.06% of Charles River Laboratories International worth $5,735,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of CRL. Fiduciary Financial Group LLC increased its position in Charles River Laboratories International by 3.9% during the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock worth $310,000 after purchasing an additional 63 shares during the period. Pinnacle Bancorp Inc. grew its holdings in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after acquiring an additional 65 shares during the period. M&T Bank Corp grew its holdings in Charles River Laboratories International by 3.4% during the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock worth $394,000 after acquiring an additional 66 shares during the period. Cornerstone Investment Partners LLC raised its position in Charles River Laboratories International by 3.7% in the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock worth $358,000 after acquiring an additional 69 shares in the last quarter. Finally, Metis Global Partners LLC lifted its holdings in Charles River Laboratories International by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company's stock valued at $318,000 after acquiring an additional 72 shares during the period. Institutional investors and hedge funds own 98.91% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other Charles River Laboratories International news, COO Birgit Girshick bought 1,514 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares of the company's stock, valued at $9,064,198.54. This trade represents a 2.83 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was acquired at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Price Performance

CRL stock traded down $1.17 during trading on Tuesday, hitting $105.43. The stock had a trading volume of 628,756 shares, compared to its average volume of 870,291. The stock has a market cap of $5.18 billion, a price-to-earnings ratio of 702.80, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The company's 50 day moving average price is $155.52 and its two-hundred day moving average price is $176.21. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same quarter in the previous year, the business posted $2.46 earnings per share. The company's revenue was down 1.1% on a year-over-year basis. On average, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. William Blair downgraded shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Morgan Stanley dropped their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their price target for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target on the stock in a report on Monday, March 3rd. Finally, Mizuho reduced their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a report on Wednesday, April 9th. One analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. Based on data from MarketBeat, Charles River Laboratories International currently has an average rating of "Hold" and a consensus target price of $182.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).